Connect with us

COVID-19

Court upholds Quebec’s unscientific and draconian Covid curfew law

Published

3 minute read

News release from the Justice Centre for Constitutional Freedoms

The Justice Centre is disappointed to announce the loss in court of a Charter challenge to Quebec’s curfew lockdown. Justice Mme Marie-France Beaulieu read her ruling aloud on January 30, 2024, in the Courthouse of Amos, in Abitibi municipal region in western Quebec.

The challenge was initiated by Stéphanie Pépin, for whom the Justice Centre provided lawyers over the past three years. On the evening of January 9, 2021, while driving to join a 9:00 p.m. protest against the curfew, Ms. Pépin was stopped by police and ticketed for being in public past the 8:00 p.m. curfew deadline.

The curfew law, which came into effect on January 9, 2021, was brought in by Quebec’s provincial government, led by Premier François Legault. It was one of the harshest lockdown policies in Canada, and Quebec was the only jurisdiction in the country to employ such a measure. It prohibited people from leaving their homes between the hours of 8:00 p.m. and 5:00 a.m. Police officers, empowered by the Public Health Act, levied fines against violators ranging from $1,000 to $6,000. The curfew came into force twice, first from January 9, 2021, until May 28, 2021, and then a second time from December 31, 2021, until January 17, 2022.

Ms. Pépin chose to fight the curfew using the Canadian Charter of Rights and Freedoms. The Justice Centre provided lawyers to Ms. Pépin, who challenged certain sections of the Public Health Act as unjustified violations of her constitutional freedoms of expression and peaceful assembly. Her hearing took place September 18-21, 2023.

As a result of a subpoena from lawyers provided by the Justice Centre, the week-long trial featured testimony from Dr. Horacio Arruda, Quebec’s National Director of Public Health during the pandemic, and Dr. Richard Massé, Arruda’s right-hand man and architect of the Public Health Act under which the curfew was enacted.

Lawyer Olivier Séguin, representing Ms. Pépin, stated, “There have been dozens of challenges to the curfew law, but this one was different. This is the first time in Canadian history that the crafters of the laws under scrutiny were questioned under oath, and it became evident they had no constitutional basis on which to act.”

The decision will be appealed.

Todayville is a digital media and technology company. We profile unique stories and events in our community. Register and promote your community event for free.

Follow Author

COVID-19

Tulsi Gabbard says US funded ‘gain-of-function’ research at Wuhan lab at heart of COVID ‘leak’

Published on

From LifeSiteNews

By Conservative Treehouse

The director of National Intelligence revealed gain-of-function ties to US funding, which could indicate that the US helped bankroll the supposed COVID lab leak.

In this segment of a remarkable interview by Megyn Kelly, Director of National Intelligence Tulsi Gabbard discusses the current Intelligence Community (IC) research into the origin of the SARS-CoV-2 pandemic (aka, COVID-19).

Gabbard talks about the U.S. government funding of “gain-of-function” research, which is a soft sounding phrase to describe the weaponization of biological agents.

Gabbard notes the gain-of-function research taking place in the Wuhan lab was coordinated and funded by the United States government, and the IC is close to making a direct link between the research and the release of the COVID-19 virus.

Additionally, Gabbard explains the concern of other biolabs around the world and then gets very close to the line of admitting the IC itself is politically weaponized (which it is but would be stunning to admit).

 

Continue Reading

COVID-19

Study finds Pfizer COVID vaccine poses 37% greater mortality risk than Moderna

Published on

From LifeSiteNews

By Nicolas Hulscher, MPH

A study of 1.47 million Florida adults by MIT’s Retsef Levi and Surgeon General Joseph Ladapo finds significantly higher all-cause mortality after Pfizer vaccination compared to Moderna

A new study of 1.47 million Florida adults by MIT’s Retsef Levi and Surgeon General Joseph Ladapo finds significantly higher all-cause, cardiovascular, and COVID-19 mortality after Pfizer vaccination.

The study titled “Twelve-Month All-Cause Mortality after Initial COVID-19 Vaccination with Pfizer-BioNTech or mRNA-1273 among Adults Living in Florida” was just uploaded to the MedRxiv preprint server. This study was headed by MIT Professor Retsef Levi, with Florida Surgeon General Dr. Joseph Ladapo serving as senior author:

Study Overview

  • Population: 1,470,100 noninstitutionalized Florida adults (735,050 Pfizer recipients and 735,050 Moderna recipients).
  • Intervention: Two doses of either:
    • BNT162b2 (Pfizer-BioNTech)
    • mRNA-1273 (Moderna)
  • Follow-up Duration: 12 months after second dose.
  • Comparison: Head-to-head between Pfizer vs. Moderna recipients.
  • Main Outcomes:
    • All-cause mortality
    • Cardiovascular mortality
    • COVID-19 mortality
    • Non-COVID-19 mortality

All-cause mortality

Pfizer recipients had a significantly higher 12-month all-cause death rate than Moderna recipients — about 37% higher risk.

  • Pfizer Risk: 847.2 deaths per 100,000 people
  • Moderna Risk: 617.9 deaths per 100,000 people
  • Risk Difference:
    ➔ +229.2 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.37 (i.e., 37% higher mortality risk with Pfizer)
  • Odds Ratio (Adjusted):
    ➔ 1.384 (95% CI: 1.331–1.439)

Cardiovascular mortality

Pfizer recipients had a 53% higher risk of dying from cardiovascular causes compared to Moderna recipients.

  • Pfizer Risk: 248.7 deaths per 100,000 people
  • Moderna Risk: 162.4 deaths per 100,000 people
  • Risk Difference:
    ➔ +86.3 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.53 (i.e., 53% higher cardiovascular mortality risk)
  • Odds Ratio (Adjusted):
    ➔ 1.540 (95% CI: 1.431–1.657)

COVID-19 mortality

Pfizer recipients had nearly double the risk of COVID-19 death compared to Moderna recipients.

  • Pfizer Risk: 55.5 deaths per 100,000 people
  • Moderna Risk: 29.5 deaths per 100,000 people
  • Risk Difference:
    ➔ +26.0 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.88 (i.e., 88% higher COVID-19 mortality risk)
  • Odds Ratio (Adjusted):
    ➔ 1.882 (95% CI: 1.596–2.220)

Non-COVID-19 mortality

Pfizer recipients faced a 35% higher risk of dying from non-COVID causes compared to Moderna recipients.

  • Pfizer Risk: 791.6 deaths per 100,000 people
  • Moderna Risk: 588.4 deaths per 100,000 people
  • Risk Difference:
    ➔ +203.3 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.35 (i.e., 35% higher non-COVID mortality risk)
  • Odds Ratio (Adjusted):
    ➔ 1.356 (95% CI: 1.303–1.412)

Biological explanations

The findings of this study are surprising, given that Moderna’s mRNA-1273 vaccine contains approximately three times more mRNA (100 µg) than Pfizer’s BNT162b2 vaccine (30 µg). This suggests that the higher mortality observed among Pfizer recipients could potentially be related to higher levels of DNA contamination — an issue that has been consistently reported worldwide:

The paper hypothesizes differences between Pfizer and Moderna may be due to:

  • Different lipid nanoparticle compositions
  • Differences in manufacturing, biodistribution, or storage conditions

Final conclusion

Florida adults who received Pfizer’s BNT162b2 vaccine had higher 12-month risks of all-cause, cardiovascular, COVID-19, and non-COVID-19 mortality compared to Moderna’s mRNA-1273 vaccine recipients.

Unfortunately, without an unvaccinated group, the study cannot determine the absolute increase in mortality risk attributable to mRNA vaccination itself. However, based on the mountain of existing evidence, it is likely that an unvaccinated cohort would have experienced much lower mortality risks. It’s also important to remember that Moderna mRNA injections are still dangerous.

As the authors conclude:

These findings are suggestive of differential non-specific effects of the BNT162b2 and mRNA-1273 COVID-19 vaccines, and potential concerning adverse effects on all-cause and cardiovascular mortality. They underscore the need to evaluate vaccines using clinical endpoints that extend beyond their targeted diseases.

Nicolas Hulscher, MPH

Epidemiologist and Foundation Administrator, McCullough Foundation

www.mcculloughfnd.org

Please consider following both the McCullough Foundation and my personal accounton X (formerly Twitter) for further content.

Reprinted with permission from Focal Points.

Continue Reading

Trending

X